European approval of Amevive delayed

Published: 21-Feb-2003

The Committee for Proprietary Medicinal Products (CPMP), the scientific advisory body of the European Medicines Evaluation Agency (EMEA), has requested more clinical information relating to Biogen's application for Amevive (alefacept) for psoriasis.


The Committee for Proprietary Medicinal Products (CPMP), the scientific advisory body of the European Medicines Evaluation Agency (EMEA), has requested more clinical information relating to Biogen's application for Amevive (alefacept) for psoriasis.

The US-based biotechnology company has with-drawn its application and plans to develop the additional clinical information necessary to obtain approval of Amevive for psoriasis patients in Europe. Developing the data and re-filing the application to gain ap-proval could take several years.

You may also like